Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04466098 · ClinicalTrials.gov registry record · Phase 2
Multiple Dosing of Mesenchymal Stromal Cells in Patients With ARDS (COVID-19)
A Phase 2 study, sponsored by Masonic Cancer Center, University of Minnesota.
- Completed
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT04466098 is a Phase 2 study that has completed, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 8 participants.
The verdict
NCT04466098, a Phase 2 study, has completed, sponsored by Masonic Cancer Center, University of Minnesota.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
This is a multi-center, randomized, placebo controlled, interventional phase 2A trial to evaluate the safety profile and potential efficacy of multi-dosing of mesenchymal stromal cells (MSC) for patients with SARS-CoV-2 associated Acute Respiratory Distress Syndrome (ARDS). After informed consent, treatment assignment will be made by computer-generated randomization to administer either MSC or vehicle placebo control with a 2:1 allocation to the MSC: placebo arm.
Interventions
- OTHER Placebo
- BIOLOGICAL Mesenchymal stromal cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2020-07-30 |
| Est. Completion | 2024-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04466098
The ClinicalTrials.gov registry entry for NCT04466098 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04466098 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04466098 about?
NCT04466098 is a clinical study titled "Multiple Dosing of Mesenchymal Stromal Cells in Patients With ARDS (COVID-19)". This is a multi-center, randomized, placebo controlled, interventional phase 2A trial to evaluate the safety profile and potential efficacy of multi-dosing of mesenchymal stromal cells (MSC) for patients with SARS-CoV-2 associated Acute Respiratory Distress Syndrome (ARDS). After informed consent, t...
What is the current status of trial NCT04466098?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2020-07-30. Estimated completion is 2024-12-31.
What interventions are being tested in trial NCT04466098?
The interventions under investigation include: Placebo (OTHER), Mesenchymal stromal cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT04466098?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.